Overview

VBL Therapeutics is an innovative, clinical-stage biotechnology company developing new treatments for immune-inflammatory diseases, including psoriasis. We are also developing new drugs to fight cancer, including thyroid cancer.

A Phase 2 efficacy and safety study is currently underway to evaluate VB-201 for the treatment of patients with psoriasis. VB-201 has successfully completed four Phase 1 clinical trials involving 120 healthy volunteers under a U.S. Investigational New Drug Application (IND).

VBL Therapeutics’ proprietary Vascular Targeting System (VTS™) technology platform has yielded VB-111, the first dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2 clinical trials in 2010.

Clinical Targets

Psoriasis and Other Inflammatory Diseases

VBL Therapeutics is pioneering a new class of drugs to treat immune-inflammatory conditions.  We have  developed a series of proprietary phospholipid analogs from the Lecinoxoid family that are rationally designed as orally available anti-inflammatory medicines addressing diseases that are imperfectly treated or prevented with current therapies.

The lead compound from this program is VB-201, which has significant potential to treat inflammation in chronic diseases such as psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and atherosclerosis. VB-201 is believed to act by inhibiting the production of the pro-inflammatory cytokines IL-12/23p40 by dendritic cells and macrophages.  VB-201 acts as a counterbalance to the pro-inflammatory immune system activity that occurs in chronic disorders without significantly affecting system-wide immune factors, and is well-positioned to either work as a monotherapy or as part of a combination therapy.

Cancer

Our innovative, proprietary platform technology, VTS™ (Vascular Targeting System), enables control of gene expression to areas in which angiogenesis is taking place to either promote or destroy newly formed blood vessels. VTS is both tissue and condition specific, allowing for targeted and limited expression to endothelial cells undergoing angiogenesis.

The VTS platform allows us to develop several different products targeting various diseases where angiogenesis is a defining feature. We have used this technology to develop two therapeutic compounds: VB-111 for oncology and VB-211 for ischemic diseases.